BYIS(SH:600581) 中国基金报·2025-11-07 12:53Core Viewpoint - The China Securities Regulatory Commission (CSRC) has mandated corrective measures for Caitong Securities due to violations in its over-the-counter (OTC) derivatives business, highlighting issues in management and compliance [2][4]. Group 1: Regulatory Actions - On November 7, the Zhejiang Securities Regulatory Bureau ordered Caitong Securities to rectify its OTC derivatives operations and issued a warning letter to senior executive Pei Gencai [2][4]. - The violations included inadequate management mechanisms for underlying assets, insufficient annual reviews of investor qualifications, and ineffective management of system permissions and passwords [4]. Group 2: Financial Performance - As of the end of Q3 2025, Caitong Securities reported derivative financial assets of 82.45 million yuan, a significant decrease of 89.69% from 800 million yuan at the end of 2024, attributed to a decline in the scale of OTC derivatives [5]. - The company's stock price was 8.59 yuan per share, with a total market capitalization of 39.89 billion yuan as of November 7 [6]. Group 3: Previous Violations - Caitong Securities has faced multiple regulatory penalties this year, including a warning for issues related to the management of its overseas subsidiaries and a fine of 1.95 million yuan for failing to comply with customer identity verification and reporting obligations [5].